diff --git a/RadLex.owl b/RadLex.owl index 17fd4c2..91677ae 100644 --- a/RadLex.owl +++ b/RadLex.owl @@ -40,7 +40,7 @@ http://www.radlex.org/RID/RID0 - + @@ -67,7 +67,7 @@ http://www.radlex.org/RID/RID0 - + @@ -89,7 +89,7 @@ http://www.radlex.org/RID/RID0 - + @@ -122,7 +122,6 @@ http://www.radlex.org/RID/RID15849 or http://www.radlex.org/RID/RID27787 - @@ -141,7 +140,7 @@ http://www.radlex.org/RID/RID0 - + @@ -167,7 +166,7 @@ http://www.radlex.org/RID/RID0 - + @@ -995175,11 +995174,11 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an No FNA - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 Not suspicious RID50505 4.1 new - ACR TI-RADS + ACR TI-RADS TI-RAD Risk Level 2 TI-RADS 2 TR2 @@ -995192,11 +995191,11 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an FNA if >=2.5cm; follow if >=1.5cm - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 Mildly suspicious RID50506 4.1 new - ACR TI-RADS + ACR TI-RADS TI-RAD Risk Level 3 TI-RADS 3 TR3 @@ -995209,12 +995208,12 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an FNA if >=1.5cm, follow if >=1cm - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 Moderately suspicious RID50507 - 4.1 + 4.1 4.1 - ACR TI-RADS + ACR TI-RADS TI-RAD Risk Level 4 TI-RADS 4 TR4 @@ -995222,7 +995221,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995233,12 +995232,12 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an FNA if >=1cm, follow if >=0.5cm - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 Highly suspicious RID50508 - 4.1 + 4.1 4.1 - ACR TI-RADS + ACR TI-RADS TI-RAD Risk Level 5 TI-RADS 5 TR5 @@ -995246,7 +995245,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995256,10 +995255,10 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50509 4.1 new - ACR TI-RADS + ACR TI-RADS presence of thyroid nodule(s) thyroid nodule @@ -995270,9 +995269,9 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50510 - 4.1 + 4.1 4.1 Cancer Care Ontario right thyroid upper @@ -995281,7 +995280,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995291,9 +995290,9 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50511 - 4.1 + 4.1 4.1 Cancer Care Ontario right thyroid middle @@ -995302,7 +995301,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995312,9 +995311,9 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50512 - 4.1 + 4.1 4.1 Cancer Care Ontario right thyroid lower @@ -995323,7 +995322,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995333,9 +995332,9 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50513 - 4.1 + 4.1 4.1 Cancer Care Ontario left thyroid upper @@ -995344,7 +995343,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995354,9 +995353,9 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50514 - 4.1 + 4.1 4.1 Cancer Care Ontario left thyroid middle @@ -995365,7 +995364,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 4.1 + 4.1 new @@ -995375,7 +995374,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-07T00:00:00 + 2019-03-07T00:00:00 RID50515 4.1 new Cancer Care Ontario @@ -995389,10 +995388,10 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-12T00:00:00 + 2019-03-12T00:00:00 RID50517 4.1 new - ACR TI-RADS + ACR TI-RADS mixed cystic and solid @@ -995402,18 +995401,18 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-03-12T00:00:00 + 2019-03-12T00:00:00 RID50519 - 4.1 + 4.1 4.1 - ACR TI-RADS + ACR TI-RADS wider than tall wider-than-tall - 4.1 + 4.1 new @@ -996191,7 +996190,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50522 4.1 new LOINC @@ -996204,7 +996203,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50523 4.1 new LOINC @@ -996218,7 +996217,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an While some might argue that excisional biopsies are a subtype of surgical biopsies (and therefore this should be a child of RID45698), others might say that excisional biopsy includes polypectomy at endoscopy, which wouldn’t typically be considered surgical. - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50524 4.1 new LOINC @@ -996231,7 +996230,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50528 4.1 new LOINC @@ -996244,7 +996243,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50529 4.1 new LOINC @@ -996257,7 +996256,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50530 4.1 new LOINC @@ -996270,7 +996269,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50531 4.1 new LOINC @@ -996283,7 +996282,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50532 4.1 new LOINC @@ -996296,7 +996295,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50533 4.1 new LOINC @@ -996309,7 +996308,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50534 4.1 new LOINC @@ -996322,7 +996321,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-19T00:00:00 + 2019-09-19T00:00:00 RID50535 4.1 new LOINC @@ -996335,7 +996334,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50536 4.1 new LOINC @@ -996348,7 +996347,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50537 4.1 new LOINC @@ -996361,7 +996360,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50538 4.1 new LOINC @@ -996374,7 +996373,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50539 4.1 new LOINC @@ -996405,7 +996404,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50540 4.1 new LOINC @@ -996418,7 +996417,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-20T00:00:00 + 2019-09-20T00:00:00 RID50541 4.1 new LOINC @@ -996433,7 +996432,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 Gastric emptying is a test that measures the time it takes for food to empty from the stomach and enter the small intestine. RID50542 4.1 new @@ -996447,7 +996446,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50543 4.1 new LOINC @@ -996460,7 +996459,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50544 4.1 new LOINC @@ -996473,7 +996472,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50545 4.1 new LOINC @@ -996486,7 +996485,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50546 4.1 new LOINC @@ -996499,7 +996498,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50547 4.1 new LOINC @@ -996513,7 +996512,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50548 4.1 new right ventricular ejection fraction @@ -996526,7 +996525,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50549 4.1 new LOINC @@ -996557,7 +996556,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50550 4.1 new LOINC @@ -996570,7 +996569,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-09-23T00:00:00 + 2019-09-23T00:00:00 RID50551 4.1 new LOINC @@ -996583,7 +996582,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-10-10T00:00:00 + 2019-10-10T00:00:00 RID50552 4.1 new LOINC @@ -996596,7 +996595,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-10-10T00:00:00 + 2019-10-10T00:00:00 UMLS:C0019004 RID50553 4.1 new @@ -996610,7 +996609,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-10-10T00:00:00 + 2019-10-10T00:00:00 RID50554 4.1 new peritoneal dialysis @@ -996622,7 +996621,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-10-10T00:00:00 + 2019-10-10T00:00:00 RID50555 4.1 new route descriptor @@ -996634,7 +996633,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-10-10T00:00:00 + 2019-10-10T00:00:00 RID50556 4.1 new LOINC @@ -996647,7 +996646,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-11-12T00:00:00 + 2019-11-12T00:00:00 RID50557 4.1 new axial plantodorsal view of calcaneus @@ -996660,7 +996659,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-11-12T00:00:00 + 2019-11-12T00:00:00 RID50558 4.1 new axial dorsoplantar view of calcaneus @@ -996673,7 +996672,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-11-12T00:00:00 + 2019-11-12T00:00:00 RID50559 4.1 new weight-bearing axial dorsoplantar view of calcaneus @@ -996699,7 +996698,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2019-11-15T00:00:00 + 2019-11-15T00:00:00 RID50560 4.1 new surgical tract @@ -996711,7 +996710,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50561 4.1 new 3D printing process @@ -996723,7 +996722,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50562 4.1 new ISO/ASTM 52900 @@ -996736,7 +996735,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50563 4.1 new ISO/ASTM 52900 @@ -996749,7 +996748,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50564 4.1 new ISO/ASTM 52900 @@ -996762,7 +996761,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50565 4.1 new ISO/ASTM 52900 @@ -996775,7 +996774,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50566 4.1 new ISO/ASTM 52900 @@ -996788,7 +996787,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50567 4.1 new ISO/ASTM 52900 @@ -996801,7 +996800,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-04-27T00:00:00 + 2020-04-27T00:00:00 RID50568 4.1 new ISO/ASTM 52900 @@ -996814,7 +996813,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-06-17T00:00:00 + 2020-06-17T00:00:00 RID50571 4.1 new TI-RADS @@ -997073,7 +997072,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-06-17T00:00:00 + 2020-06-17T00:00:00 RID50572 PI-RADS v2.1 set of PI-RADS terms @@ -997085,7 +997084,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-06-18T00:00:00 + 2020-06-18T00:00:00 [LI-RADS] Not having the properties of a mass; without distorting or destroying parenchyma RID50573 4.1 new @@ -997099,7 +997098,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an - 2020-06-18T00:00:00 + 2020-06-18T00:00:00 [LI-RADS] Lesion treated by any therapy RID50574 4.1 new @@ -997119,7 +997118,7 @@ or diffuse multifocal enhancement NOT corresponding to a focal finding on T2W an • External beam radiation Surgical resection physically removes part of the liver and is not considered locoregional therapy. Systemic administration of chemotherapeutic or biologic agents is also not considered locoregional therapy. - 2020-06-18T00:00:00 + 2020-06-18T00:00:00 [LI-RADS] A therapy that targets a specific lesion or part of the liver without physically removing it. RID50575 4.1 new @@ -997136,7 +997135,7 @@ Systemic administration of chemotherapeutic or biologic agents is also not consi [LI-RADS] Parenchymal distortion may represent a malignant neoplasm such as HCC with infiltrative appearance or heterogeneous parenchyma due to underlying severe cirrhosis. Loss of normal hepatic architecture includes loss of visualization of normal portal triads or hepatic veins. Parenchymal distortion when identified on surveillance ultrasound is categorized US-3 Positive by US LI-RADS. - 2020-06-18T00:00:00 + 2020-06-18T00:00:00 [LI-RADS] Parenchymal area ≥ 10 mm seen on ultrasound with one or more of the following characteristics: • Ill-defined area of heterogeneity @@ -997154,7 +997153,7 @@ following characteristics: - 2020-06-18T00:00:00 + 2020-06-18T00:00:00 RID50577 4.1 new distortion observation @@ -997171,7 +997170,7 @@ Washout can be seen in the entire observation or only in part(s) of the observat Can apply to any enhancing observation, even if no APHE, but some arterial phase enhancement must occur. Completely nonenhancing observations (e.g., cysts) cannot be characterized as having washout. If APHE is present, the areas with APHE and washout do not need to coincide. Washout with CEUS is different from “washout” on CT/MRI, since the microbubbles used in CEUS are blood pool agent. As a result, washout on CEUS is thought to represent true washout. - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 [LI-RADS] Reduction in enhancement over time relative to background liver, following some degree of arterial phase enhancement, resulting in hypoenhancement relative to background liver. CEUS washout is divided by degree into mild vs. marked and by onset into late vs. early. @@ -997200,7 +997199,7 @@ CEUS washout is divided by degree into mild vs. marked and by onset into late vs Early washout is usually marked in degree. See “marked washout” for definition. - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Washout on CEUS in which onset is within 60 seconds from contrast injection. RID50580 4.1 new @@ -997214,7 +997213,7 @@ See “marked washout” for definition. - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Washout on CEUS in which onset is after 60 seconds from contrast injection. RID50581 4.1 new @@ -997228,7 +997227,7 @@ See “marked washout” for definition. - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Pronounced washout on CEUS in which the observation becomes black or “punched out” within 2 minutes from contrast injection. RID50582 4.1 new @@ -997243,7 +997242,7 @@ See “marked washout” for definition. If the observation becomes black or “punched out” after 2 minutes then the degree of washout is still considered mild - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Washout on CEUS in which the observation does not become black or punched out within 2 minutes from contrast injection. RID50583 4.1 new @@ -997259,7 +997258,7 @@ See “marked washout” for definition. On US and CEUS, typically 10-20 frames/second. CT and MRI can also acquire images in real time, but this is not commonly performed with these modalities. - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Acquisition of images in real time. RID50584 4.1 new @@ -997273,7 +997272,7 @@ CT and MRI can also acquire images in real time, but this is not commonly perfor - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 A series of brief CEUS image acquisitions, each lasting a few seconds and repeated at intervals of about 30 to 60 seconds without any imaging in between. RID50585 4.1 new @@ -997288,7 +997287,7 @@ CT and MRI can also acquire images in real time, but this is not commonly perfor ECA - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 [LI-RADS} Contrast agents with predominantly extracellular distribution after intravenous injection. RID50586 4.1 new @@ -997312,7 +997311,7 @@ CT and MRI can also acquire images in real time, but this is not commonly perfor Differs from dynamic contrast-enhanced imaging where images are acquired continuously over minutes to enable perfusion analysis. Multiphase imaging is not synonymous with dynamic contrast-enhanced (DCE) perfusion imaging where images are acquired continuously over minutes to enable perfusion analysis - 2020-06-25T00:00:00 + 2020-06-25T00:00:00 Acquisition of images at two or more different phases after intravenous contrast injection RID50587 4.1 new @@ -997329,7 +997328,7 @@ Multiphase imaging is not synonymous with dynamic contrast-enhanced (DCE) perfus Nonrim APHE can be seen in the entire observation or only in part(s) of the observation. Enhancing part(s) must be brighter than liver in arterial phase. Nonrim APHE includes diffuse and homogeneous (uniform), diffuse and heterogeneous (non-uniform), scattered (patchy, spotty), nodule-in-nodule, or mosaic enhancement. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 Subtype of APHE in which APHE is NOT most pronounced in periphery of observation. RID50588 4.1 new @@ -997351,7 +997350,7 @@ Nonrim APHE includes diffuse and homogeneous (uniform), diffuse and heterogeneou Can apply to any enhancing observation, even if no APHE. Nonperipheral “washout” can be seen in the entire observation or only in part(s) of the observation. RadLex 4.1: Synonyms not added when identical to synonyms for "washout appearance" - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 Subtype of “washout” in which apparent washout is NOT most pronounced in observation periphery. RID50589 4.1 new @@ -997391,7 +997390,7 @@ Nonperipheral “washout” can be seen in the entire observation or only in par If a “capsule” is visible as an enhancing rim on PVP, DP or TP images AND as a nonenhancing rim on other images, characterize as enhancing “capsule”, NOT as nonenhancing “capsule”. A border visible only as an enhancing rim in the HBP should not be characterized as a “capsule”. RadLex 4.1: Synonyms not added when identical to synonyms for "capsule appearance (liver)" - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 Subtype of “capsule” visible as an enhancing rim in PVP, DP, or TP. RID50590 4.1 new @@ -997406,7 +997405,7 @@ A border visible only as an enhancing rim in the HBP should not be characterized - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 Size increase of a mass, less than threshold growth. Any of the following: • Size increase < 50% over any time period @@ -997428,7 +997427,7 @@ Any of the following: The presence of targetoid appearance suggests iCCA or other non-HCC malignancy, but it does not exclude HCC. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 [LI-RADS] Target-like imaging morphology. The center and periphery of a mass have different imaging characteristics. RID50592 4.1 new @@ -997447,7 +997446,7 @@ Any of the following: Rim APHE is a subtype of targetoid morphology. The presence of rim APHE suggests iCCA or other non-HCC malignancy, but it does not exclude HCC. Rim APHE can be smooth or irregular. It can vary in thickness. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 Subtype of APHE in which arterial phase enhancement is most pronounced in observation periphery. RID50593 4.1 new @@ -997470,7 +997469,7 @@ Rim APHE can be smooth or irregular. It can vary in thickness. Delayed central enhancement is a subtype of targetoid morphology. The area of delayed enhancement in a lesion may be central, eccentric, or heterogeneous, but not peripheral. The presence of delayed central enhancement suggests iCCA or other non-HCC malignancy, but it does not exclude HCC. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 [LI-RADS] Area of postarterial phase enhancement most pronounced in the inside rather than in the periphery of the lesion. RID50594 4.1 new @@ -997488,7 +997487,7 @@ The presence of delayed central enhancement suggests iCCA or other non-HCC malig [LI-RADS] The presence of targetoid restriction suggests iCCA or other non-HCC malignancy, but it does not exclude HCC. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 [LI-RADS] Concentric pattern on DWI characterized by restricted diffusion in observation periphery with less restricted diffusion in observation center. RID50595 4.1 new @@ -997506,7 +997505,7 @@ The presence of delayed central enhancement suggests iCCA or other non-HCC malig [LI-RADS] The presence of targetoid TP or HBP appearance suggests iCCA or other nonHCC malignancy, but it does not exclude HCC. - 2020-06-26T00:00:00 + 2020-06-26T00:00:00 [LI-RADS] Concentric pattern in TP or HBP characterized by moderate-to-marked hypointensity in observation periphery with milder hypointensity in center. RID50596 4.1 new @@ -997528,7 +997527,7 @@ If there is any doubt about the presence of enhancing soft tissue in vein, the L Tumor in vein and enhancing soft tissue in vein are related but not identical terms: • Tumor in vein is a LI-RADS category • Enhancing soft tissue in vein is the imaging criterion for tumor in vein - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] Presence of enhancing soft tissue in vein, regardless of visualization of parenchymal mass. RID50597 4.1 new @@ -997542,7 +997541,7 @@ Tumor in vein and enhancing soft tissue in vein are related but not identical te - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] Unenhanced US visibility as discrete nodule or mass corresponding to CT- or MRI-detected observation. RID50598 4.1 new @@ -997561,7 +997560,7 @@ Tumor in vein and enhancing soft tissue in vein are related but not identical te Transitional phase hypointensity can be seen in the entire observation or only in part(s) of the observation. Does not qualify as washout appearance. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 Intensity in the transitional phase less than liver. RID50599 4.1 new @@ -997578,7 +997577,7 @@ Does not qualify as washout appearance. Hepatobiliary phase hypointensity can be seen in the entire observation or only in part(s) of the observation. Does not qualify as washout appearance. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 Intensity in the hepatobiliary phase less than liver. RID50600 4.1 new @@ -997601,7 +997600,7 @@ Does not qualify as washout appearance. • DWI: hyperintense • Contrast-enhanced T1WI: nonenhancing • HBP: hypointense - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 Subtype of “capsule” that does not show enhancement on any image. RID50601 4.1 new @@ -997619,7 +997618,7 @@ Does not qualify as washout appearance. While strictly a property, this is included as a descriptor in order to place similar terms together, and allow synonyms of different grammatical form [LI-RADS] There are no strict criteria for change in size that may be due to artifact, technique differences, or measurement error. Rather, this is determined by the user’s judgement. Appears to have replaced "diamater stability" in LI-RADS 2020. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] No significant change in observation size measured on exams ≥ 2 years apart in absence of treatment. Practically, this means that there is either • No measurable change in size @@ -997642,7 +997641,7 @@ OR Appears to have replaced "diamater reduction" in LI-RADS 2020. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] Spontaneous decrease in size over time, that cannot be attributed only to artifact, technique differences, measurement error, or resorption of blood products. RID50603 4.1 new @@ -997661,7 +997660,7 @@ OR [LI-RADS] Characteristic imaging feature of cysts and some hemangiomas. If spleen is iron overloaded, then compare to fluid-filled structures such as bile ducts, simple cysts, or cerebrospinal fluid. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] Intensity on T2WI greater than non-ironoverloaded spleen. RID50604 4.1 new @@ -997682,7 +997681,7 @@ If spleen is iron overloaded, then compare to fluid-filled structures such as bi ECP During the postarterial extracellular phase, enhancement of the liver is mainly due to extracellular distribution of a contrast agent. Does not apply to blood pool agents. - 2020-06-29T00:00:00 + 2020-06-29T00:00:00 [LI-RADS] A broad term referring to: • PVP and DP, if an extracellular agent or gadobenate is given • PVP only, if gadoxetate is given @@ -997698,7 +997697,7 @@ Does not apply to blood pool agents. - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50606 4.1 new imaging specialty @@ -997710,7 +997709,7 @@ Does not apply to blood pool agents. - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50607 4.1 new imaging subspecialty @@ -997723,7 +997722,7 @@ Does not apply to blood pool agents. AB - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50608 4.1 new abdominal radiology @@ -997736,7 +997735,7 @@ Does not apply to blood pool agents. BR - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50609 4.1 new breast imaging @@ -997749,7 +997748,7 @@ Does not apply to blood pool agents. CA - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50610 4.1 new cardiac radiology @@ -997762,7 +997761,7 @@ Does not apply to blood pool agents. CH - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50611 4.1 new chest radiology @@ -997775,7 +997774,7 @@ Does not apply to blood pool agents. ER - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50612 4.1 new emergency radiology @@ -997788,7 +997787,7 @@ Does not apply to blood pool agents. GI - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50613 4.1 new GI radiology @@ -997802,7 +997801,7 @@ Does not apply to blood pool agents. GU - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50614 4.1 new GU radiology @@ -997816,7 +997815,7 @@ Does not apply to blood pool agents. HN - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50615 4.1 new head and neck @@ -997830,7 +997829,7 @@ Does not apply to blood pool agents. IR - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50616 4.1 new interventional radiology @@ -997843,7 +997842,7 @@ Does not apply to blood pool agents. MI - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50617 4.1 new molecular imaging @@ -997856,7 +997855,7 @@ Does not apply to blood pool agents. MK - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50618 4.1 new musculoskeletal radiology @@ -997869,7 +997868,7 @@ Does not apply to blood pool agents. NR - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50619 4.1 new neuroradiology @@ -997882,7 +997881,7 @@ Does not apply to blood pool agents. OB - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50620 4.1 new OB/GYN radiology @@ -997895,7 +997894,7 @@ Does not apply to blood pool agents. OI - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50621 4.1 new oncologic imaging @@ -997908,7 +997907,7 @@ Does not apply to blood pool agents. OT - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50622 4.1 new other imaging subspecialty @@ -997921,7 +997920,7 @@ Does not apply to blood pool agents. PD - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50623 4.1 new pediatric radiology @@ -997934,7 +997933,7 @@ Does not apply to blood pool agents. QI - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50624 4.1 new quality improvement @@ -997948,7 +997947,7 @@ Does not apply to blood pool agents. RS - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50625 4.1 new imaging research @@ -997962,7 +997961,7 @@ Does not apply to blood pool agents. VA VI - 2020-07-14T00:00:00 + 2020-07-14T00:00:00 RID50626 4.1 new vascular imaging @@ -997974,7 +997973,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50628 4.1 new LOINC @@ -997987,7 +997986,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50629 4.1 new LOINC @@ -998000,7 +997999,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50630 4.1 new LOINC @@ -998013,7 +998012,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50631 4.1 new LOINC @@ -998026,7 +998025,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50632 4.1 new LOINC @@ -998039,7 +998038,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50633 4.1 new LOINC @@ -998053,7 +998052,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50634 4.1 new LOINC @@ -998066,7 +998065,7 @@ Does not apply to blood pool agents. - 2020-09-16T00:00:00 + 2020-09-16T00:00:00 RID50635 4.1 new LOINC @@ -998079,7 +998078,7 @@ Does not apply to blood pool agents. - 2020-10-16T00:00:00 + 2020-10-16T00:00:00 RID50636 4.1 new LOINC @@ -998092,7 +998091,7 @@ Does not apply to blood pool agents. - 2020-12-09T00:00:00 + 2020-12-09T00:00:00 RID50638 4.2 new endocrine surgery @@ -998104,7 +998103,7 @@ Does not apply to blood pool agents. - 2020-12-09T00:00:00 + 2020-12-09T00:00:00 RID50639 4.2 new thyroidectomy @@ -998127,7 +998126,7 @@ Does not apply to blood pool agents. - 2021-05-24T00:00:00 + 2021-05-24T00:00:00 RID50640 4.2 new LOINC @@ -998140,7 +998139,7 @@ Does not apply to blood pool agents. - 2021-05-24T00:00:00 + 2021-05-24T00:00:00 RID50641 4.2 new LOINC diff --git a/tests/robot-report-profile.txt b/tests/robot-report-profile.txt index 00c1f4c..22a64bb 100644 --- a/tests/robot-report-profile.txt +++ b/tests/robot-report-profile.txt @@ -1 +1,2 @@ -ERROR file:./tests/sparql/robot/leading_trailing_multi_whitespace.rq \ No newline at end of file +ERROR file:./tests/sparql/robot/leading_trailing_multi_whitespace.rq +ERROR file:./tests/sparql/robot/value_outside_declared_range.rq diff --git a/tests/sparql/robot/value_outside_declared_range.rq b/tests/sparql/robot/value_outside_declared_range.rq new file mode 100644 index 0000000..7b47e9d --- /dev/null +++ b/tests/sparql/robot/value_outside_declared_range.rq @@ -0,0 +1,29 @@ +PREFIX rdfs: +PREFIX owl: +PREFIX xsd: + +# +# Part of the RadLex ontology SPARQL test suite. Bindings to this query represent violations of the test. +# +# Test that every annotation value matches the range its property declares. A string-ranged or date-ranged +# property must not carry a language-tagged value or an IRI, and a date-ranged property must carry an +# xsd:dateTime. A mismatch crashes the Protege annotation editor (issue #8) and is invisible to a reasoner, +# because OWL 2 Direct Semantics ignores annotations. +# +# VIOLATIONS will be bindings that have, on ?entity, ?property, and ?value respectively: +# - The entity carrying the value. +# - The annotation property. +# - The value that does not match the declared range. +# +SELECT ?entity ?property ?value +WHERE { + ?property a owl:AnnotationProperty ; + rdfs:range ?range . + VALUES ?range { xsd:string xsd:dateTime } + ?entity ?property ?value . + FILTER( + isIRI(?value) + || LANG(?value) != "" + || (?range = xsd:dateTime && DATATYPE(?value) != xsd:dateTime) + ) +}